Iron overload is common in patients undergoing allogeneic hematopoietic cell transplantation (HCT) for hematologic disorders. Serum ferritin, a marker of tissue iron overload, was measured immediately before transplant in adult patients undergoing myeloablative HCT from matched sibling or unrelated donors. The effect of elevated pretransplant ferritin (defined as ferritin X1000 ng/ml) on day 100 mortality, overall survival, acute GVHD and infectious complications was assessed. Data on 190 patients were analyzed. In univariate analysis, the highferritin group had increased day 100 mortality (20 vs 9%, P ¼ 0.038), decreased overall survival (log-rank test: P-value ¼ 0.004), increased acute GVHD/death (63 vs 43%, P ¼ 0.009) and increased incidence of blood stream infections (BSIs)/death (60 vs 44%, P ¼ 0.042). In a multivariate analysis, high ferritin was associated with increased risk of death (Cox model: hazard ratio ¼ 2.28, P ¼ 0.004), increased day 100 mortality (generalized linear model (GLM) odds ratio ¼ 3.82, P ¼ 0.013), increased incidence of acute GVHD/death (GLM odds ratio ¼ 3.11, P ¼ 0.001) and increased risk of BSI/death (GLM odds ratio ¼ 1.99, P ¼ 0.032). The results remained similar when serum ferritin was considered a continuous variable. Elevated serum ferritin adversely impacts on overall survival and increases the likelihood of acute GVHD and BSI after allogeneic HCT.
Introduction
Iron overload is common in patients undergoing hematopoietic cell transplantation (HCT) for hematologic disorders. 1 The adverse impact of iron overload on transplant outcome has been demonstrated most convincingly in patients undergoing HCT for thalassemia, where class 3 patients (who have extensive liver damage from iron overload) have higher transplant-related mortality. 2 However, there is recent evidence that the same may be the case with patients undergoing allogeneic HCT for other indications as well. 3 Besides increased transplant-related mortality, other complications attributed to iron overload include fungal infections, hepatic dysfunction and hepatic venoocclusive disease (VOD). [4] [5] [6] [7] [8] We prospectively examined the effect of iron overload as measured by pretransplant serum ferritin on transplant outcomes in a sample of 190 patients undergoing myeloablative HCT from matched sibling and matched unrelated donors (MUD). We particularly examined the impact of elevated serum ferritin on day 100 mortality, overall survival (OS), infectious complications, regimen-related toxicity and acute GVHD.
Methods

Study population
Serum ferritin levels were obtained prospectively from 190 consecutive patients who underwent allogeneic HCT from April 2005 to August 2006. The study was approved by the institutional review board of City of Hope Medical Center. Patients aged over 18 years who were recipients of sibling or MUD HCT and received a myeloablative transplant conditioning regimen were included in the study. Patients and donors had to be fully matched at HLA-A, B and DR alleles. Serum ferritin, serum iron, transferring saturation and total iron-binding capacity were measured on admission for HCT, before initiation of the conditioning regimen.
Definitions
Elevated serum ferritin was defined as a level X1000 ng/ml. Acute GVHD was graded according to standard criteria. 9 Blood stream infections (BSIs) were defined as the recovery of a recognized pathogen from one or more blood cultures or the recovery of a common skin contaminant from two or more blood cultures or from a single blood culture in a patient with an intravascular device for which appropriate antimicrobial therapy was initiated. The major end points analyzed were mortality at 100 days after HCT, OS, incidence of acute GVHD (grade II or greater) or death, incidence of BSI or death, VOD and diffuse alveolar hemorrhage/idiopathic pneumonia syndrome (DAH/IPS). The diagnosis categories used were 'lymphoma/myeloma' and 'acute leukemia/myeloid malignancies'; the latter also including patients with BM failure syndromes.
Statistical analysis
Univariate proportions were compared using Fisher's exact test. Serum ferritin level is related to the number of blood transfusions, which would be expected to differ depending on diagnosis. To separate the effect on the outcome variable due to ferritin level from that due to diagnosis, we conditioned on the diagnosis. In the univariate case, we implemented a stratified Mantel Haenszel test conditioning on the diagnosis category, whereas in the multivariate case we implemented generalized linear models (GLMs) with a binomial family and logit link to model the relationship between categorical outcome variables with the covariates believed to be associated with either the end point of interest (diagnosis category, donor type, conditioning strength, disease activity and gender) or the level of serum ferritin (diagnosis category). Significance was assessed using a Wald test. Univariate comparisons for differences in survival curves were made using a log-rank test. Cox proportional hazards models were used to model the relationship among OS, the explanatory variable namely serum ferritin and covariates listed above. Significance was assessed using a Wald test. The categorical variables were determined as follows: elevated serum ferritin (indicator for X1000 ng/ml of ferritin), donor type (indicator for MUD patients), diagnosis category (indicator for acute leukemia/ myeloid malignancy), conditioning strength (indicator for full intensity), disease activity at HCT (indicator for active disease) and gender (indicator for male recipient). The level of significance was determined to be 0.05.
Results
Patient characteristics
The outcomes of 190 subjects were analyzed. Of these, 107 received matched sibling transplants and the remaining 83 received MUD transplants. Table 1 provides detailed demographic and treatment information. The median age of the subjects was 46 years (range 20-69). The high-and low-ferritin groups were well matched with regard to sex and age. The proportion of patients with high serum ferritin (X1000 ng/ml) was similar among sibling and MUD transplant recipients (44 vs 45%, P ¼ 1.0), and disease status groups (active disease: 46%, remission: 41%, P ¼ 0.46). The median pretransplant serum ferritin of the 190 patients was 952 ng/ml with values ranging from 10 to 10 000 ng/ml. Ferritin values of the different diagnosis subgroups are shown in Figure 1 . Total 18% patients with lymphoma or myeloma had ferritin values X1000 ng/ml compared to 52% of patients in the acute leukemia/myeloid malignancy group (Po0.0001), consistent with our hypothesis that iron overload would be less prevalent among patients with lymphoproliferative disorders as opposed to those with acute leukemias, myeloid malignancies and BM failure syndromes. Other serum iron studies are shown in Table 2 .
Impact of high serum ferritin on day 100 mortality A total of 27 of the 190 patients (14%) died within 100 days of HCT. Univariate analysis showed that there were more deaths in the high-ferritin group (X1000: 20% vs o1000: 9%; Fisher's exact test P ¼ 0.038). This association of high ferritin with higher day 100 mortality persisted when an exact stratified Mantel Haenszel test was used to account for the diagnosis category (for lymphoma/myeloma, ferritin X1000: 38%; o1000: 16%, for acute leukemia/myeloid malignancy, ferritin X1000: 18%; o1000: 6%, P ¼ 0.013).
In the GLM for day 100 mortality, high serum ferritin increased the odds of mortality by 3.82-fold (confidence interval, CI: 1.32-11.0, Wald test P ¼ 0.013). Male gender also increased the odds of mortality (odds ratio: 7.67, CI: 2.15-27.3, P ¼ 0.002), although having a diagnosis in acute leukemia/myeloid malignancy category decreased the odds (odds ratio ¼ 0.27, CI: 0.082-0.91, P ¼ 0.034). Donor type, conditioning intensity and disease activity at transplant did not contribute significantly to day 100 mortality. Examining the effect with the two diagnosis categories separately (lymphoma/myeloma and acute leukemia/myeloid malignancy), high serum ferritin and male sex retained significance as predictors of day 100 mortality for the larger acute leukemia/myeloid malignancy category (n ¼ 145) whereas they were no longer significant in the smaller lymphoma/myeloma group (n ¼ 45).
We also considered serum ferritin as a continuous variable implementing a log base 2 transformation in the model. Again, the association of increasing ferritin with higher mortality was maintained (odds ratio: 1.51, CI: 1.07-2.14) for a doubling in ferritin (Wald test P ¼ 0.02).
Impact of high serum ferritin on overall survival The 190 patients were followed for a mean of 209 days (s.d. ¼ 136)). A total of 56 patients died during the followup period; 27 in the first 100 days and 29 after that time. Univariate analysis for differences in survival curves showed increased risk of death in the high-ferritin group (P ¼ 0.004). The OS of high-and low-ferritin groups is shown in Figure 2 .
Results of the Cox proportional hazards model were similar to those obtained by univariate analysis. A higher risk of death was seen in the high-ferritin category (hazard ratio ¼ 2.28, CI: 1.29-4.02, P ¼ 0.004), among male patients (hazard ratio ¼ 2.75, CI: 1.48-5.09, P ¼ 0.001), patients receiving full-intensity conditioning (hazard ratio ¼ 2.46, CI: 1.42-4.27, P ¼ 0.001) and MUD transplants (hazard ratio ¼ 1.70, CI: 0.99-2.9, P ¼ 0.054). No significant impact of disease status at HCT or diagnosis category on OS was evident using this model.
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The strong relationship between elevated serum ferritin and increased mortality after HCT was maintained when the categorical variable of ferritin was replaced by a continuous variable implementing a log base 2 transformation. For a doubling in the amount of ferritin, the risk of death was increased by 34% (hazard ratio ¼ 1.34, CI: 1.09-1.65, P ¼ 0.005).
Impact of high serum ferritin on acute GVHD Acute GVHD (grade II or above) occurred in 92 patients (48%). In addition, 7 patients died within 100 days of HCT without experiencing GVHD for a sum total of 99 patients (52%) with events (acute GVHD or death) within the first 100 days after HCT.
There were a greater number of events in the high-ferritin group (ferritin X1000: 63%, o1000: 43%; P ¼ 0.009). A similar result was obtained using an exact stratified Mantel Haenszel test conditioning on the diagnosis category (acute leukemia/myeloid malignancy: X1000: 63%; o1000: 42%; lymphoma/myeloma: X1000: 63%; o1000: 46%; P ¼ 0.009).
Using GLM to examine the combined end point of acute GVHD or death in the first 100 days after HCT, being in When serum ferritin was examined as a continuous variable implementing a log base 2 transformation, the relationship between higher ferritin level and increased acute GVHD/mortality was maintained (odds ratio ¼ 1.20, CI: 0.987-1.46 for a doubling in ferritin, P ¼ 0.068), but the increase was not statistically significant. Donor type and conditioning strength still remained significant predictors of acute GVHD/death. Similar results were obtained if the seven patients who died in the first 100 days after HCT without experiencing GVHD are excluded from the analysis (data not shown). 
Figure 2 Iron overload adversely impacts overall survival (OS) after allogeneic hematopoietic cell transplantation (HCT). OS of the whole cohort is shown in (a). (b)
Survival of the lymphoma/myeloma group, (c) the survival of the acute leukemia/myeloid malignancy group, which includes patients with acute leukemia, myelodysplasia, myeloproliferative disorders and BM failure syndromes. In cases (a) and (c) the low ferritin group (o1000 ng/ml) (solid line) shows significantly better survival compared to the high-ferritin group (X1000 ng/ml) (dashed line). Tick marks represent censoring.
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Impact of high serum ferritin on blood stream infection risk after HCT A total of 89 patients experienced a BSI and another 8 patients died within the first 100 days without having a BSI for a sum total of 97 (51%) of 190 patients for this combined end point. There was a significant difference between the high-and low-ferritin groups for the BSI end point (o1000 ¼ 44%, X1000: 60%, P ¼ 0.042) ( Table 3) . This difference remained significant when conditioned on the diagnosis category (acute leukemia/myeloid malignancy: X1000: 57%; o1000: 42%; lymphoma/Myeloma: X1000: 88%; o1000: 49%, P ¼ 0.022). Implementing GLM to study effects of ferritin on BSI in a multivariate analysis, the odds for developing BSI were higher in the high-ferritin category (odds ratio ¼ 1.99, CI: 1.06-3.75, Wald test P ¼ 0.032). None of the other covariates (diagnosis category, donor type, conditioning strength, disease activity and gender) were significant for increased risk of BSI/death in this model. One of the major determinents for increased BSI is time to neutrophil engraftment, which is the longest for cord blood transplants followed by BM and PBSC transplants in descending order. When the data were examined for each of these donor products, the results were similar to those obtained for the full data set (data not shown).
Elevated serum ferritin increased the odds for BSI/death (odds ratio ¼ 1.22) for a doubling in ferritin, when examined as a continuous variable on a log base 2 scale (CI: 1.01-1.48, P ¼ 0.041).
Serum ferritin and regimen-related toxicity
Only two regimen-related toxicities namely hepatic VOD and DAH/IPS were analyzed. The number of patients who suffered either of these complications is low. Six patients developed hepatic VOD grade 2 or above, whereas fourteen patients developed DAH/IPS grade 2 or above. The mean ferritin levels of patients experiencing toxicity were compared to those who did not and the difference was not significant for either complication using a two-sample t-test assuming unequal variances.
Discussion
Our results show that iron overload measured by pretransplant serum ferritin is a strong predictor of day 100 mortality and OS after allogeneic HCT. In addition, we have shown that elevated ferritin is a risk factor for development of acute GVHD and BSI after HCT. This prognostic impact of elevated serum ferritin on mortality after HCT remained significant even after accounting for factors like disease status, donor type and diagnosis. Although we used an arbitrary level of 1000 ng/ml to define the high-ferritin group, the results remained similar when ferritin was considered as a continuous variable, suggesting that is it preferable to undergo HCT with the least amount of tissue iron. Pretransplant serum ferritin has been included as a variable in a recently published prognostic scoring system for predicting survival after allogeneic HCT for acute leukemia and myelodysplasia. This scoring system included age, disease, stage at HCT and cytogenetics in addition to elevated ferritin and was highly predicitive of survival after allogeneic HCT. 10 The adverse impact of high ferritin on OS after HCT in nonthalassemic patients has been shown in two previous studies. In a retrospective review of 590 patients, Armand et al. 3 showed declining OS with each increasing quartile of serum ferritin. However, after accounting for relevant covariates, the deleterious effect on OS was significant only for patients with myelodysplastic syndrome or acute leukemia. Our results were similar and showed an adverse impact of iron overload on the OS of the whole group as well as the 'acute leukemia/myeloid malignancy' subgroup, but not for the 'lymphoma/myeloma' subgroup. However, it must be noted that the number of patients in the 'lymphoma/myeloma' subgroup was small (N ¼ 45) and hence the impact of iron overload on the outcome of patients with lymphoid malignancies requires further investigation. In a small study of 25 patients (of which 10 patients underwent allogeneic HCT and the rest autologous HCT), Altes et al. 11 showed significantly worse OS by multivariate analysis for their very high ferritin group (defined as ferritin X3000 ng/ml). No studies have systematically examined the effect of iron overload on the OS of patients undergoing autologous HCT. This will be difficult to demonstrate given the lower mortality from autologous HCT and the lower serum ferritin levels of patients undergoing autologous HCT compared to those undergoing allogeneic HCT.
Our data show a strong association between iron overload and moderate to severe acute GVHD when ferritin was examined both as a categorical and as a continuous variable. This effect could be explained by the increased free-radical-mediated tissue injury (discussed later) on exposure to the conditioning regimen in ironoverloaded patients, as tissue injury is the initiating event in acute GVHD pathogenesis. Therefore, it is likely that an association between iron overload and acute GVHD would be more significant in allogeneic HCT using high-dose conditioning. In their retrospective analysis, Armand et al. did not find an association between hyperferritinemia and acute GVHD. Therefore, our finding of increased acute GVHD risk in iron-overloaded patients remains to be confirmed in future prospective studies.
Natural resistance to infection is dependent on maintaining an extremely low concentration of free ionic iron in tissue fluids. 12 Increased availability of iron in iron overload states provides an essential nutrient for bacterial and fungal growth and impairs host defenses. Iron overload as a risk factor for bacterial and fungal infections has been Iron overload and hematopoietic cell transplant V Pullarkat et al demonstrated in hereditary as well as secondary hemochromatosis. 13 A similar association of iron overload with infectious risk has been suggested in previous studies both in allogeneic and autologous HCT. The infections associated include bacteremia as well as invasive aspergillosis and mucormycosis. [4] [5] [6] 14, 15 Consistent with these previous reports, we were able to demonstrate that iron overload is associated with an increased risk for BSI after allogeneic HCT. Owing to the low incidence of Aspergillus and other mold infections in our cohort, we were unable to analyze the specific association of iron overload with these fungal infections.
We also attempted to analyze the association of hepatic VOD and DAH/IPS with iron overload, as tissue injury induced by the conditioning regimen is important in the development of these complications. Owing to the rarity of these regimen-related toxicities, we were not able to systematically study their association with serum ferritin. The mean ferritin level in patients with these complications in our study was not significantly different from those who did not experience these toxicities. An association of hepatic VOD with iron overload has been suggested in previous reports 8, 16, 17 and deserves further evaluation in large trials. A role for iron overload in the pathogenesis of DAH/IPS has also been postulated. 16 It is well known that serum ferritin being an acute-phase reactant is not an accurate measure of body iron status in patients who have ongoing acute infectious or inflammatory diseases. However, serum ferritin remains the most cost-effective and practical measure and is certainly the most widely available. We used the ferritin measurement obtained immediately on admission for allogeneic HCT, especially as patients who have acute infections would not be admitted for an allogeneic HCT. Moreover, serum iron levels (a marker of inflammation due to the drop in its plasma carrier protein transferrin in inflammatory states) were in the normal range in both high-and low-ferritin groups of our study. Imaging studies such as measurement of hepatic and cardiac iron are more accurate and have less variability than does serum ferritin and are becoming more available and could provide a more accurate assessment of iron overload in future studies. 18 The toxicity of iron overload is attributed to the increased generation of hydroxyl radicals by nontransferrin bound iron (NTBI) on exposure to the conditioning regimen. 19, 20 In a study of 10 patients undergoing allogeneic HCT, transferrin saturation rose and NTBI rapidly appeared after initiation of the conditioning regimen, peaked as early as day 4 and was detectable for an average of 14 days. 19 Hydroxyl radicals generated by NTBI can induce tissue damage by various mechanisms including oxidative damage to proteins and lipid peroxidation. 21 Increased tissue injury in iron-overloaded patients undergoing allogeneic HCT may explain the increased acute GVHD seen in our study as tissue injury in relevant organs is the initiating event in the multistep pathogenesis of acute GVHD. NTBI also increases the risk of bacterial and fungal infections by providing an essential nutrient for these organisms. 12 As most patients who eventually undergo allogeneic HCT are initially treated outside of transplant centers, attempts to minimize iron overload should be initiated by the initial health care providers in the community. The acute nature of many hematologic disorders for which allogeneic HCT is performed, coupled with the slow effect of currently available iron chelators makes it difficult to lower iron stores adequately after referral for allogeneic HCT. In disorders where allogeneic HCT is considered later in the disease course, careful attention should be given to iron overload, especially in patients requiring transfusions. Ineffective hematopoiesis and consequent increased iron absorption may contribute to increased NTBI in some infrequently transfused patients, particularly those with MDS. 22 Therefore, low-and intermediate-risk MDS patients may be a particular group to target for early iron chelation therapy, especially as the impact of iron overload on allogeneic HCT outcome appears to be pronounced in this patient group. 3 In summary, iron overload is a strong predictor of an adverse outcome after allogeneic HCT. The possibility of iron overload should be entertained in patients who are potential candidates for an allogeneic HCT and attempts made early in the disease course to minimize red cell transfusion use and initiate chelation. There is a need for large multicenter prospective studies with longer follow up to precisely determine the immediate and long-term impact of iron overload in patients undergoing allogeneic HCT.
